5-(3,6-dihydro-2H-pyran-4-yl)-2-(4-(methylthio)phenyl)-4-(m-tolyl)-1H-imidazole | 1435770-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3,6-dihydro-2H-pyran-4-yl)-2-(4-(methylthio)phenyl)-4-(m-tolyl)-1H-imidazole
• 英文别名: 5-(3,6-dihydro-2H-pyran-4-yl)-4-(3-methylphenyl)-2-(4-methylsulfanylphenyl)-1H-imidazole
• CAS: 1435770-56-1
• 化学式: C₂₂H₂₂N₂OS
• 分子量: 362.495
• InChiKey: SZOBHCNUNMTFSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(3,6-dihydro-2H-pyran-4-yl)-2-(4-(methylthio)phenyl)-4-(m-tolyl)-1H-imidazole 在 dipotassium peroxodisulfate 作用下， 以 水 、 溶剂黄146 为溶剂， 以95%的产率得到US10865384, Example 4a
  参考文献：
  名称：

  Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells

  摘要：

  The p38 alpha mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38 alpha MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38 alpha MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.103
• 作为产物：
  描述：

  4-(m-tolylethynyl)tetrahydro-2H-pyran-4-ol 在 potassium permanganate 、 ammonium acetate 、 copper(II) acetate monohydrate 作用下， 以 1,4-二氧六环 、 水 、 溶剂黄146 为溶剂， 生成 5-(3,6-dihydro-2H-pyran-4-yl)-2-(4-(methylthio)phenyl)-4-(m-tolyl)-1H-imidazole
  参考文献：
  名称：

  Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells

  摘要：

  The p38 alpha mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38 alpha MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38 alpha MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.103